Metabolon Release: Metabolomics Aids in Understanding Mechanisms of Commonly Used Drugs

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced a new study has been published which seeks to better understand the toxicological uncertainties of fenofibrate. Co-authored by Metabolon and Mitsubishi Tanabe Pharma, “Untargeted Metabolomic Profiling as an Evaluative Tool of Fenofibrate-Induced Toxicology in Fischer 344 Male Rats” appears in Toxicologic Pathology (Vol. 37, No. 4, 521-535, 2009).